• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Integra LifeSciences Holdings (IART) Builds Ahead Of Results, Is The Stock Still 29% Undervalued?

    Simply Wall St·07/19/2026 08:17:14
    Listen to the news

    Integra LifeSciences Holdings (IART) is back in focus as investors look ahead to its upcoming quarterly results, following a period of topping earnings expectations and receiving broadly favorable analyst commentary.

    See our latest analysis for Integra LifeSciences Holdings.

    The recent excitement around Integra LifeSciences Holdings sits against a sharp rebound in the stock, with a 90 day share price return of 72.49% and a year to date share price return of 60.28%. However, the 3 year and 5 year total shareholder returns are still down 57.56% and 71.90% respectively, suggesting momentum has turned positive in the short term while longer term holders remain underwater.

    If you are looking at Integra LifeSciences Holdings as part of a broader healthcare toolkit, this could be a good moment to evaluate opportunities in AI driven medical and diagnostics businesses through our screener of 39 healthcare AI stocks

    For Integra LifeSciences Holdings, a 72.49% rebound in 90 days can signal either improving confidence in the business or a sentiment swing running ahead of fundamentals. This makes the next step a closer look at valuation.

    Most Popular Narrative: 28.7% Undervalued

    Integra LifeSciences Holdings last closed at $19.25, while the most followed narrative assigns a fair value of $27.00, framing the recent share price rebound as only a partial repricing.

    Analysts broadly agree that Integra's Compliance Master Plan and supply chain upgrades will stabilize operations and restore revenue, however, this may actually drive a structural step change in cost efficiency and supply reliability, leading to gross margin and earnings expansion well beyond conservative estimates as operational bottlenecks are permanently resolved across legacy and newly acquired sites.

    Read the complete narrative.

    Want to see how Integra moves from a large reported loss to positive earnings, with reworked margins and a reset profit multiple at the center of the story? The narrative leans on measured revenue growth, a clear path to profitability, and a future valuation level that sits below the wider Medical Equipment peer group. Curious which assumptions need to hold for that $27.00 fair value to stack up over time?

    Result: Fair Value of $27.00 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Integra LifeSciences Holdings still faces meaningful risks, including ongoing regulatory and quality issues, plus pricing pressure that could weigh on revenue and margin assumptions supporting the $27.00 fair value narrative.

    Find out about the key risks to this Integra LifeSciences Holdings narrative.

    Next Steps

    Seeing both optimism and caution around Integra LifeSciences Holdings, it makes sense to move quickly, check the underlying data yourself, and then weigh up the 3 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Integra LifeSciences Holdings?

    Do not stop with Integra LifeSciences Holdings. Broaden your watchlist with fresh ideas sourced from data driven screeners that highlight different ways to build a resilient portfolio.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.